Cystex Plus (methenamine/sodium salicylate)

Methenamine is commercially available as methenamine hippurate and methenamine mandelate; dosage is expressed in terms of the salt.

Dosage of salicylate salts must be carefully adjusted according to individual requirements and response, using the lowest possible effective dosage.

Unless otherwise directed by a clinician, choline salicylate, magnesium salicylate, sodium salicylate should not be used for self-medication of pain for longer than 10 days in adults; choline salicylate and sodium salicylate should not be used for self-medication of pain for longer than 5 days in children. Pain of such intensity and duration may indicate a pathologic condition requiring medical evaluation and supervised treatment. These preparations should not be used in adults or children for self-medication of marked fever (greater than 39.5degreesC), fever persisting longer than 3 days, or recurrent fever, unless otherwise directed by a clinician, since such fevers may indicate serious illness requiring prompt evaluation and treatment by a physician. In addition, these preparations should not be used in adults or children for self-medication of sore throat for longer than 2 days, unless otherwise directed by a clinician.

To minimize the risk of overdosage, no more than 5 doses of any of these drugs should be administered to children for analgesia or antipyresis in any 24-hour period, unless otherwise directed by a clinician.

Choline salicylate, magnesium salicylate, sodium salicylate, and combination preparations containing choline salicylate and magnesium salicylate are administered orally. The drugs should usually be given with food or a large quantity (240 mL) of water or milk to minimize gastric irritation. Although rarely necessary, sodium salicylate may also be administered by slow IV infusion. Trolamine salicylate is applied topically.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in rats and rabbits using methenamine hippurate have not revealed evidence of harm to the fetus. A slight increase in the stillborn rate and slight impairment of weight gain and survival of live-born offspring was reported in a study in pregnant dogs using oral methenamine in dosages equivalent to the human dosage. There are no adequate and well-controlled studies to date using methenamine hippurate or methenamine mandelate in pregnant women, and the drugs should be used during pregnancy only when clearly needed.

Although safe use of methenamine or its salts during pregnancy has not been definitely established, the drugs have been used in pregnant women without adverse effects to the fetus. One manufacturer of methenamine hippurate states that safety during the last trimester is suggested, but not definitely proven.

The effects of methenamine during labor and delivery are unknown and there are no recognized uses for the drug during labor or delivery.

Because methenamine is distributed into milk and because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.